NLRP3 and myeloid sarcoma: Pharmacological inhibitors of NLRP3 have demonstrated the ability to attenuate oligodendrocyte loss and promote remyelination in MS preclinical models, suggesting that inflammasome modulation may represent a viable avenue for therapeutic intervention [250].